Author

S. Schloer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2

Frequent Co-Authors

U. Rescher· 3 shared A. Mecate-Zambrano· 2 shared J. Goretzko· 2 shared L. Brunotte· 2 shared S. Ludwig· 2 shared V. Gerke· 2 shared A. L. Linard Matos· 1 shared C. M. Grimm· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

U. Rescher

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Leukocyte adhesion is governed by endolysosomal two pore channel 2 (TPC2)

J. Goretzko, N. Heitzig, K. Thomas, E. K. Krogsaeter, J. Nass, A. L. Linard Matos, T. Wegner, S. Schloer, V. Gerke, J. Rossaint, F. Glorius, F. Bracher, C. M. Grimm, U. Rescher

The paper shows that TPC2 regulates endothelial cell surface P-selectin by controlling CD63 transfer from endosomes to Weibel-Palade bodies, affecting leukocyte recruitment during inflammation.

bioRxiv · Sep 28, 2021 · PreprintImmunology

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

S. Schloer, L. Brunotte, J. Goretzko, A. Mecate-Zambrano, N. Korthals, V. Gerke, S. Ludwig, U. Rescher

This study identifies fluoxetine and other FIASMAs as inhibitors of SARS-CoV-2 entry by targeting endolysosomal acidification and cholesterol accumulation.

Emerging Microbes & Infections · Oct 17, 2020Peer-reviewedMicrobiology

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro

U. Rescher, S. Schloer, L. Brunotte, A. Mecate-Zambrano, S. Zheng, J. Tang, S. Ludwig

This study evaluates the antiviral effects of combining remdesivir with repurposed drugs fluoxetine and itraconazole, showing >90% inhibition of SARS-CoV-2 particle production in vitro.

bioRxiv · Oct 16, 2020Pharmacology & Toxicology